Evaluating a new treatment for prostate cancer using targeted radioligand therapy
Official title: Systematic evaluation of toxicity and therapeutic efficacy in CD46 directed radioligand therapy
Funded at University of California, San Francisco · NIH-11075325 · Data updated 2026-11-12
This study is looking at a new treatment for prostate cancer that uses a special type of targeted radiation therapy, and it's designed to see how well it works and what side effects it might have, so that patients can get better care with less harm to healthy tissues.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project start | May 1, 2023 |
| Project end | April 30, 2028 |
| Funding year | 2025 |
| Award (this year) | $664,448 |
| NIH project number | 5R01CA279203-03 |
| Project ID | NIH-11075325 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with metastatic prostate cancer who are seeking new treatment options.
✕Less likely to help
Patients with non-metastatic prostate cancer or those who do not express the CD46 antigen may not benefit from this research.
What this research studies
This research focuses on improving a targeted therapy for prostate cancer that uses CD46 directed radioligand therapy. The team will systematically assess how effective this treatment is and what side effects it may cause by using advanced cancer models. They will analyze the results through various methods, including histology and metabolomics, to ensure that the therapy effectively targets cancer cells while minimizing harm to normal tissues. The study involves a collaborative team of experts in nuclear medicine, cancer metabolism, and drug development.
Why it matters
Potential benefit: If successful, this research could lead to a more effective and safer treatment option for patients with prostate cancer.
How similar studies have gone: Previous research has shown promise in using targeted radioligand therapies for cancer treatment, indicating potential success for this approach.
Where this research is happening
-
University of California, San Francisco
San Francisco, United States Active
Researchers
- Principal investigator: Flavell, Robert Richard — University of California, San Francisco
- Study coordinator: Flavell, Robert Richard
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.